New York Assembly Bill A08767

New York 2025-2026 Regular Session

• Introduced: 6/2/25
• Refer: 6/2/25

Caption

Authorizes a licensed pharmacist to administer a United States Food and Drug Administration-approved reversible progestin-only contraceptive injection.

Summary

This bill would amend the New York Education Law to expand the scope of practice for licensed pharmacists. In addition to existing authority to administer certain injectable medications, pharmacists would be expressly authorized to administer a United States Food and Drug Administration-approved reversible progestin-only contraceptive injection when prescribed or ordered by a licensed prescriber and when acting within their scope of practice under state regulations. The measure is structured as a targeted change to section 6801 of the Education Law and would take effect one year after becoming law, with immediate authorization for any needed regulatory changes before the effective date. It does not create a new contraceptive product or prescribing authority; rather, it allows pharmacists to deliver an already approved injectable contraceptive under existing clinical and regulatory oversight.

Impact

The bill would modify New York’s pharmacist scope-of-practice rules by adding contraceptive injection administration to the list of services pharmacists may provide. It would affect the Education Law provisions governing pharmacist practice and could expand patient access to birth control, especially in settings where pharmacy access is more convenient than a physician’s office. The bill would also require state agencies to adopt or update regulations to implement the new authority.

Sentiment

No committee transcript or vote record is provided, so there is no direct evidence of debate or formal support/opposition in the materials supplied. Based on the bill text alone, the measure appears to be framed as a practical access-to-care expansion, with a neutral, technical approach focused on pharmacist authorization and regulatory implementation.

Contention

The main policy issue likely to generate discussion is whether pharmacists should be permitted to administer contraceptive injections, which raises questions about scope of practice, patient access, and regulatory oversight. Potential concerns could include training requirements, liability, and coordination with prescribers, while supporters would likely emphasize convenience, access to reproductive healthcare, and use of existing FDA-approved medication. No specific objections or proponents are identified in the provided record.